VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

被引：0

作者：

Coleman, R. L. ^{[1
]}

Fleming, G. F. ^{[2
]}

Brady, M. F. ^{[3
]}

Swisher, E. ^{[4
]}

Steffensen, K. D. ^{[5
,6
]}

Friedlander, M. ^{[7
,8
]}

Okamoto, A. ^{[9
]}

Moore, K. ^{[10
]}

Ben-Baruch, N. ^{[11
]}

Werner, T. L. ^{[12
]}

Oaknin, A. ^{[13
]}

Nam, J-H. ^{[14
]}

Leath, C. A., III ^{[15
]}

Nicum, S. ^{[16
]}

Cella, D. ^{[17
]}

Sullivan, D. M. ^{[18
]}

Ansell, P. J. ^{[18
]}

Dinh, M. ^{[18
]}

Aghajanian, C. ^{[19
]}

Bookman, M. A. ^{[20
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Gynecol Oncol & Reprod Med, Houston, TX 77030 USA

[2] Univ Chicago Med, Dept Med, Chicago, IL USA

[3] Roswell Park Canc Inst, NRG Oncol Stat & Data Ctr, Buffalo, NY 14263 USA

[4] Univ Washington, Dept Obstet & Gynecol, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[5] Vejle Hosp, Dept Oncol, Vejle, Denmark

[6] Univ Southern Denmark, Odense, Denmark

[7] UNSW, Prince Wales Clin Sch, Med Oncol, Sydney, NSW, Australia

[8] Prince Wales Hosp, Sydney, NSW, Australia

[9] Jikei Univ, Sch Med, Obstet & Gynecol, Tokyo, Japan

[10] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA

[11] Kaplan Med Ctr, Oncol, Rehovot, Israel

[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[13] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[14] Univ Ulsan, Coll Med, Asan Med Ctr, Obstet Gynecol, Seoul, South Korea

[15] Univ Alabama Birmingham, Div Gynecol Oncol, Birmingham, AL USA

[16] Oxford Univ Hosp, Dept Oncol, Oxford, England

[17] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[18] AbbVie Inc, Oncol, N Chicago, IL USA

[19] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA

[20] Kaiser Permanente Calif Northern Calif, Gynecol Oncol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页码：895 / 896

页数：2

共 17 条

[1] Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma
Kar T.
Kar A.
Dhal I.
Panda S.
Biswal P.
Nayak B.
Rout N.
Samantray S.
The Journal of Obstetrics and Gynecology of India, 2017, 67 (6) : 432 - 441
[2] Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Kummar, Shivaani
Oza, Amit M.
Fleming, Gini F.
Sullivan, Daniel M.
Gandara, David R.
Naughton, Michael J.
Villalona-Calero, Miguel A.
Morgan, Robert J., Jr.
Szabo, Peter M.
Youn, Ahrim
Chen, Alice P.
Ji, Jiuping
Allen, Deborah E.
Lih, Chih-Jian
Mehaffey, Michele G.
Walsh, William D.
McGregor, Paul M., III
Steinberg, Seth M.
Williams, P. Mickey
Kinders, Robert J.
Conley, Barbara A.
Simon, Richard M.
Doroshow, James H.
CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1574 - 1582
[3] Transformation of primary human fallopian tube secretory epithelial cells: A cell of origin for high-grade serous ovarian carcinoma
Karst, Alison M.
Leyanon, Keren
Drapkin, Ronny
CANCER RESEARCH, 2011, 71
[4] A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma Is it Clinically Relevant?
Lawson, Barrett C.
Euscher, Elizabeth D.
Bassett, Roland L.
Liu, Jinsong
Ramalingam, Preetha
Zhong, YanPing
Fleming, Nicole D.
Malpica, Anais
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (02) : 206 - 213
[5] TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma
Lawson, Barrett C.
Yang, Richard K.
Euscher, Elizabeth D.
Ramalingam, Preetha
Malpica, Anais
HUMAN PATHOLOGY, 2021, 115 : 76 - 83
[6] Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)
Duska, Linda R.
Java, James J.
Cohn, David E.
Burger, Robert A.
GYNECOLOGIC ONCOLOGY, 2015, 139 (02) : 221 - 227
[7] Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218): An NRG Oncology/Gynecologic Oncology Group Study (ADS-1236) EDITORIAL COMMENT
Van Le, Linda
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2016, 71 (01) : 24 - 26
[8] PALBOCICLIB PLUS LETROZOLE COMBINATION AFTER PROGRESSION ON SECOND-LINE CHEMOTHERAPY FOR WOMEN WITH ER/PR-POSITIVE HIGH-GRADE SEROUS OR ENDOMETRIOID OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER (LACOG 1018)
Damian, Fernanda
Zibetti Dal Molin, Graziela
Rodrigues, Angelica
De Carvalho Calabrich, Aknar
Werutsky, Gustavo
Filho, Elias Abdo
Jimenez, Mirela Foresti
Rebelatto, Taiane
De Jesus, Rafaela
Cristina De Melo, Andreia
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A243 - A243
[9] A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens.
Moore, Kathleen N.
Rimel, Bj
Agarwal, Shefali
Balser, John
Martell, Robert E.
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018
Damian, Fernanda Bronzon
De Melo, Andreia Cristina
Dal Molin, Graziela Zibetti
Rodrigues, Angelica Nogueira
de Carvalho Calabrich, Aknar Freire
Werutsky, Gustavo
Abdo Filho, Elias
Rebelatto, Taiane Francieli
de Jesus, Rafaela Gomes
Jimenez, Mirela Foresti
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 →